Phase 1 Stomach Cancer Trial, Recruiting NCT06253871 Sponsor: Iambic Therapeutics, Inc Condition: Stomach Cancer
Back to Stomach Cancer

Phase 1 Stomach Cancer Trial, Recruiting

NCT06253871
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You have a cancer that has come back or stopped responding to treatment, and your cancer has a specific change (alteration) in a protein called HER2
  • Your cancer has continued to grow after your last treatment, or you were unable to tolerate your last treatment
  • Your cancer can be measured on a scan using standard measurement guidelines
  • You are generally able to carry out daily activities with little or no limitation (confirm with trial site for exact fitness level required)
  • Your blood counts, liver, and kidneys are working well enough as shown by recent blood tests
  • Your heart is pumping blood effectively, at 50% or above (confirmed by a heart scan)
  • You are able to swallow tablets or capsules

Who may not be able to join:

  • You have a serious heart condition
  • You are currently infected with HIV, unless your HIV is very well controlled with treatment and blood tests show it is undetectable
  • You currently have an active liver infection, such as hepatitis A, B, or C
  • You have severe, ongoing nausea or vomiting, problems absorbing food, or have had a significant portion of your small bowel removed, which could stop you absorbing the medication properly
  • You have diabetes that is not well controlled
  • You have previously had a transplant of a solid organ (such as a kidney, liver, or heart)
  • You have a history of a moderate or severe bleed in the brain, or any brain bleed within the last 28 days
  • You have a history of a non-infectious lung condition called interstitial lung disease (ILD), unless it was mild and has completely cleared up
  • You currently have a brain tumour that needs urgent treatment right away

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Iambic Therapeutics, Inc., Senior Medical Director, Iambic Therapeutics, Inc

Phone: 619-330-5499

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Iambic Therapeutics, Inc
Registry
ClinicalTrials.gov
Start date
25 March 2024
Est. completion
1 December 2027

Where this trial is recruiting

🇫🇷 France 🇮🇪 Ireland 🇮🇹 Italy 🇳🇱 Netherlands 🇰🇷 South Korea 🇪🇸 Spain 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Incidence and severity of dose limiting toxicities (DLTs) (Part 1 only); Incidence and severity of adverse events (AEs); Pharmacokinetic (PK) parameters; Confirmed objective response rate (cORR); Confirmed central nervous system ORR (CNS-cORR); Frequency of IAM1363 dose modifications, including treatment discontinuations; Incidence and severity of clinical laboratory abnormalities; Incidence of ECG abnormalities

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov